Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

Mosegui, Gabriela Bittencourt Gonzalez; Antoñanzas, Fernando; Vianna, Cid Manso de Mello; Rojas, Paula de Íscar de

doi:10.1186/s42358-021-00172-w

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have reported that better functionality is associated with a lower level of pain and structural damage and better work productivity, contributing to a good clinical response according to the CDAI. 32,33 Overall, some sociodemographic and clinical factors, such as the patient's sex, marker levels, and clinical characteristics at baseline, are predictive of poor disease control over time. 34 Despite the observed reduction in disease activity, approximately 30-50% of the patients did not achieve adequate control of PsA.…”

Section: Discussionmentioning

confidence: 99%

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

et al. 2022

View full text Add to dashboard Cite

BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple joints. It is associated with psoriasis and treated with synthetic and biologic drugs. OBJECTIVE: The objective of this study was to assess the outcomes of patients who received biologic therapy with tumor necrosis factor (TNF) inhibitors in terms of effectiveness, safety, functionality, and quality of life. DESIGN AND SETTING: A prospective observational study was performed at a single center in Belo Horizonte, Brazil. METHODS: Patients with PsA who received their first TNF inhibitor treatment were followed up for 12 months. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BAS-DAI) and Clinical Disease Activity Index (CDAI). Functionality was measured using the Health Questionnaire Assessment (HAQ), and quality of life was evaluated using the European Quality of Life Five Dimensions (EQ-5D). Multiple linear regression was used to identify predictors of the clinical response at 12 months. RESULTS: A total of 143 patients treated with adalimumab or etanercept were evaluated. Most of the clinical measures were significantly improved at 12 months. However, 31%-51% of the patients did not achieve good clinical control. No differences were observed between adalimumab and etanercept, except for poor functionality at 12 months among patients treated with etanercept. The main predictors of a worse clinical response were female sex, etanercept use, poor functionality, or lower quality of life at baseline. The main adverse reactions were alopecia, headache, injection site reaction, sinusitis, flu, dyslipidemia, and infections. CONCLUSION: TNF inhibitor therapy was effective and safe. However, despite improvements in clinical measures, most patients did not achieve satisfactory control of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Even with biosimilars in the region, the economic effort to access these medications is still higher than in developed countries such as Spain or the United States. 62 , 63 …”

Section: Access To Biological Therapies In Latammentioning

confidence: 99%

“…Even with biosimilars in the region, the economic effort to access these medications is still higher than in developed countries such as Spain or the United States. 62,63 Mexico. The healthcare system in Mexico is divided into private and public sectors.…”

Section: Access To Biological Therapies In Mexico Central America And...mentioning

confidence: 99%

IBD barriers across the continents: a continent-specific analysis: Latin America

Queiroz

Martins

Quaresma

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Latin America (LATAM) is a large region comprising 47 countries and territories. Each one carries a different cultural and historical background, diverse political systems, and a particular approach to healthcare management. There is a lack of high-quality data on the epidemiology of inflammatory bowel diseases (IBD) in this region, including broad and detailed information about the penetration of biological and advanced therapies as treatment strategies. From an IBD perspective, patients experience, in general, fragmentations and inequities in the healthcare systems, with different and usually delayed access to qualified health services. This review explores the barriers to accessing IBD care throughout LATAM. The authors compiled data from multiple sources, such as studies focusing on epidemiology, biological penetration, and surgical rates. In addition, overall access to IBD treatments was assessed through a questionnaire distributed to physicians in LATAM via email and direct messaging to capture local perspectives.

show abstract

Comparative price analysis of biological medicines: disparities generated by different pricing policies

Pontes,

Ribeiro,

Albuquerque

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Biological medicines have been assuming an important role among the therapeutic options for several diseases, however, due to their complex production process, the products obtained from this technology have a high added value and do not reach the purchasing power of most patients, which overwhelms the budget of health systems. With the development of biosimilars, which have reduced production costs, it is expected that access to biological medicines will become broader. However, in Brazil, the criteria for determining the price of biosimilars, unlike the generic policy in the country, do not foresee a price reduction due to the reduction of development costs.Objective: To understand the impact of the current model of economic regulation on the availability and access of these products in the country, based on a comparative analysis in selected countries, and identify trends that can help to expand the availability and access to biological medicines.Method: Quantitative and qualitative study, to identify the variation between the entry prices of biological medicines in Brazil and in selected countries, as well as the differences in the economic regulation policies established in these countries.Results: The results demonstrate that the current pricing model in Brazil has generated distortions in the prices of biosimilars in the market, which, consequently, makes it difficult for the population to access this category of products, in addition to allowing unsustainable market practices for the systems of public and private health in Brazil. It was also found that most of the analyzed countries, unlike Brazil, seek to harmonize the prices of different brands of the same molecule marketed in the country and with the international market, in addition to establishing incentive policies for indication and replacement by biosimilars, which expands the participation of biosimilars in the market significantly.Conclusion: Based on the data presented, it is concluded that it is essential to build a broader political and regulatory debate on the market for biologicals and biosimilars in the country to guarantee the access of the Brazilian population to more cost-effective technologies, generate a more competitive market and consequently contribute to the financial sustainability of health systems.

show abstract

Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

Cited by 3 publications

References 8 publications

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study

IBD barriers across the continents: a continent-specific analysis: Latin America

Comparative price analysis of biological medicines: disparities generated by different pricing policies

Contact Info

Product

Resources

About